Program
actinium AC-225 dotatate
Also written as “RYZ101”, “RYZ101 Dose Level 1” and “RYZ101 Dose Level 2”.
Its studies are mostly in Breast Neoplasms · Gastro-enteropancreatic neuroendocrine tumor, led by Bristol-Myers Squibb.
Furthest: phase 3, since Jul 20, 20223 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 33 open or running | phase 3since Jul 20, 2022 | Jul 20, 2022 | Dec 2026phase 3 · NCT05477576 |
- Named in Bristol-Myers Squibb’s own pipeline as
RYZ101
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 20, 2022First study: phase 3 study in Gastro-enteropancreatic neuroendocrine tumorFirst studyNCT05477576 · 343 enrolled · United States, Belgium, Brazil and more
- Sep 16, 2022Phase 1 study in SCLC,Extensive StageNCT05595460 · 21 enrolled · United States, Puerto Rico
- Sep 3, 2024Phase 2 study in Breast NeoplasmsNCT06590857 · 64 planned · United States, Canada, South Korea
Ahead
- Dec 2026Primary completion: phase 3 study in Gastro-enteropancreatic neuroendocrine tumorNCT05477576
- Jul 2027Primary completion: phase 1 study in SCLC,Extensive StageNCT05595460
- Oct 2028Primary completion: phase 2 study in Breast NeoplasmsNCT06590857
TargetBeta
“A radioconjugate consisting of the somatostatin analog tyrosine-3-octreotate (Tyr3-octreotate or TATE) labeled, via the macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA), with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic…”NCIt, read by Claude
Other programs on SSTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Octreotiderule | Novartis | phase 4 | 36 |
| Paltusotinerule | Vertex Pharmaceuticals | phase 3 | 9 |
| SSTR2-targeting Non-peptide Drug Conjugate CRN09682rule | Vertex Pharmaceuticals | phase 2 | 1 |
| Actinium Ac 225 SSTR2-targeted Agent RYZ401 | Bristol-Myers Squibb | phase 1 | 1 |
| NTQ6179 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06590857Breast Neoplasms · United States, Canada, South Korea | 2 | Recruiting | Oct 2028 | 64 |
| NCT05595460SCLC,Extensive Stage · United States, Puerto Rico | 1 | Active, not recruiting | Jul 2027 | 21 |
| NCT05477576Gastro-enteropancreatic neuroendocrine tumor · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Dec 2026 | 343 |
How it is read
Names in the registry
- “RYZ101”, 2 entries
- “RYZ101 Dose Level 1”, 1 entry
- “RYZ101 Dose Level 2”, 1 entry
- “RYZ101 Dose Level 3”, 1 entry
- “RYZ101 Dose Level -1”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Gastro-enteropancreatic neuroendocrine tumor, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.